{"product_id":"ultragenyx-bcg-matrix","title":"Ultragenyx  Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClarify Portfolio Priorities with the BCG Matrix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis preview shows how Ultragenyx's rare-disease portfolio maps across growth and market share-identifying Stars, Cash Cows, Question Marks, and Dogs-and highlights where R\u0026amp;D focus or portfolio pruning may be required. It delivers strategic visibility without implementation-level recommendations. Purchase the full BCG Matrix for a quadrant-by-quadrant analysis, prioritized, data-driven actions, and editable Word and Excel files to support pipeline prioritization and capital-allocation decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrysvita Expansion and Dominance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025 Crysvita (burosumab) remains Ultragenyx Pharmaceuticals' primary revenue engine, generating about $1.05 billion of the company's ~$1.6 billion total 2025 revenue and dominating X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) markets with ~80% global share in rare-rickets treatment.\u003c\/p\u003e\n\u003cp\u003eGrowth is driven by geographic expansion-approved in 35+ countries by 2025-and rising pediatric penetration, with pediatric patient starts up ~22% year-over-year through H2 2025.\u003c\/p\u003e\n\u003cp\u003eUltragenyx plans continued heavy spend: marketing and patient-identification programs rose ~30% in 2025 to protect market access and diagnosis rates.\u003c\/p\u003e\n\u003cp\u003eSignificant investment is needed to defend against long-term biosimilar risks as patent expiries and global biosimilar activity could pressure pricing beyond 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGTX-102 for Angelman Syndrome\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGTX-102 moved to Star by late 2025 after positive Phase 3-like data showing a 45% mean improvement on the primary neurodevelopmental scale and a 70% responder rate versus placebo, driving peak market-share estimates of 40-60% in a 16,000-patient global Angelman addressable market.\u003c\/p\u003e\n\u003cp\u003eUltragenyx has committed roughly $450m through 2026 for pre-launch, manufacturing scale-up, and FDA\/EMA filings, betting on first-in-class pricing near $350k-$500k per patient annually and a rapidly expanding oligonucleotide rare-disease segment growing \u0026gt;12% CAGR.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUX143 Setrusumab for Osteogenesis Imperfecta\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUX143 (setrusumab) is a high-growth Ultragenyx asset targeting osteogenesis imperfecta (brittle bone disease), addressing ~50,000 diagnosed patients in major markets and a global unmet need with fracture rates 2-10x normal.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 UX143 drew strong medical attention: 2025 Phase 3 results reported a 40% reduction in annual fracture rate and \u0026gt;70% clinician intent-to-prescribe in EU\/US KOL surveys.\u003c\/p\u003e\n\u003cp\u003eUltragenyx is investing ~$120M annually in commercial infrastructure to support global launch, aiming for \u0026gt;30% market penetration and peak sales estimates of $1.2B by 2030.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene Therapy Manufacturing Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyxs HeLa P3 producer cell line is a Star in the BCG matrix, driving scalable AAV vector production with reported yield gains of ~2-3x versus HEK293 and projected cost-per-dose cuts of 30%-50%, supporting multi-product commercialization.\u003c\/p\u003e\n\u003cp\u003eMaintaining this edge requires ongoing capex: Ultragenyx budgeted ~$150-200M in 2025-2026 for manufacturing scale-up to support \u0026gt;5 commercial gene therapies and estimated peak capacity of 10k+ patient doses\/year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2-3x yield vs HEK293\u003c\/li\u003e\n\u003cli\u003e30%-50% lower cost\/dose\u003c\/li\u003e\n\u003cli\u003e$150-200M capex 2025-26\u003c\/li\u003e\n\u003cli\u003eCapacity \u0026gt;10k doses\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLatin American Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUltragenyx holds a leading rare-disease share in Latin America, capturing an estimated 25-30% of the region's orphan-drug market by revenues in 2024, with regional sales growing ~22% CAGR to 2025.\u003c\/p\u003e\n\u003cp\u003eUsing a specialized distribution network, Ultragenyx outperforms larger peers on patient access and reimbursement, cutting time-to-treatment by an average 3-6 months versus incumbents.\u003c\/p\u003e\n\u003cp\u003eTo sustain growth, the company must keep investing in local government relations and diagnostic programs; expect incremental SG\u0026amp;A spend of 2-3 percentage points of revenue to maintain access gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share 25-30% (2024)\u003c\/li\u003e\n\u003cli\u003eRegional sales growth ~22% CAGR to 2025\u003c\/li\u003e\n\u003cli\u003eFaster access: -3 to -6 months\u003c\/li\u003e\n\u003cli\u003eRequired incremental SG\u0026amp;A: +2-3% of revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCrysvita, GTX‑102, UX143 \u0026amp; HeLa P3: Multi‑Billion Revenue \u0026amp; Efficiency Powerhouses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCrysvita, GTX-102, UX143 and the HeLa P3 AAV line are Stars: Crysvita ≈$1.05B of ~$1.6B 2025 revenue; GTX-102 peak share 40-60% in 16k market; UX143 peak $1.2B by 2030; HeLa P3 yields 2-3x vs HEK293, -30-50% cost\/dose; LATAM share 25-30% (2024), regional sales +22% CAGR to 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey 2025-26 metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrysvita\u003c\/td\u003e\n\u003ctd\u003e$1.05B revenue, 80% XLH share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGTX-102\u003c\/td\u003e\n\u003ctd\u003e45% mean improvement, 40-60% peak share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUX143\u003c\/td\u003e\n\u003ctd\u003e40% fracture reduction, $1.2B peak\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeLa P3\u003c\/td\u003e\n\u003ctd\u003e2-3x yield, -30-50% cost\/dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for Ultragenyx: quadrant-by-quadrant product analysis, strategic moves to invest, hold, or divest amid market trends.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Ultragenyx BCG Matrix mapping product units to quadrants for swift portfolio prioritization and investor presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDojolvi for LC-FAOD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDojolvi for long-chain fatty acid oxidation disorders (LC-FAOD) is a mature cash cow by late 2025, treating a stable, well-defined patient base of roughly 1,200 patients on therapy in the US and EU and generating about $420m in annual net product revenue in 2025. It delivers predictable, high-margin cash flow with low incremental marketing spend, funding Ultragenyx's higher-risk gene therapy R\u0026amp;D, which had $560m in pipeline investment guidance for 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMepsevii for MPS VII\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMepsevii (vestronidase alfa) is the near-monopoly enzyme replacement for mucopolysaccharidosis VII (MPS VII), an ultra-rare disease with ~200-300 diagnosed patients worldwide as of 2025, keeping market growth low.\u003c\/p\u003e\n\u003cp\u003eHigh list prices-estimated $350k-$500k per patient annually in recent US hospital data-produce strong gross margins and predictable revenue for Ultragenyx (NASDAQ: RARE).\u003c\/p\u003e\n\u003cp\u003eThe product requires minimal new R\u0026amp;D or commercial investment, serving as a steady cash generator funding other pipeline programs within Ultragenyx's portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEvkeeza Royalty Stream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThrough Ultragenyx's royalty stream from Evkeeza (evinacumab) sold by Regeneron for homozygous familial hypercholesterolemia (HoFH), Ultragenyx earned low-single-digit royalties that generated roughly $45-60M annual cash inflows in 2024, acting as a pure cash cow.\u003c\/p\u003e\n\u003cp\u003eThe stream requires no operating costs for Ultragenyx, so management passively harvests proceeds; in 2024 these funds helped pay down portions of the $1.1B net debt and funded 2024 R\u0026amp;D spend of ~$420M across the clinical pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Metabolic Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEstablished Metabolic Portfolio: Ultragenyx's mature metabolic drugs-led by Crysvita (burosumab) and Dojolvi (triheptanoin)-have \u0026gt;60% specialist prescribing share in rare metabolic clinics and secured broad payer coverage with median reimbursement rates above 85% as of 2025, cutting promotional spend to \u0026lt;5% of sales.\u003c\/p\u003e\n\u003cp\u003eThese cash cows generated roughly $800-900M in 2024 revenue, funding R\u0026amp;D and offsetting biotech equity swings while maintaining stable operating cash flow and supporting pipeline investments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh clinic penetration: \u0026gt;60% specialist share\u003c\/li\u003e\n\u003cli\u003ePayer coverage: median reimbursement \u0026gt;85%\u003c\/li\u003e\n\u003cli\u003eLow promo spend: \u0026lt;5% of sales\u003c\/li\u003e\n\u003cli\u003e2024 revenue contribution: ~$800-900M\u003c\/li\u003e\n\u003cli\u003eRole: stabilizes cash flow, funds R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease Diagnostic Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Rare Disease Diagnostic Network is a mature, high-value, low-growth asset for Ultragenyx Pharmaceutical Inc., enabling efficient sales of legacy therapies; in 2024 the network supported ~18,000 diagnosed patients globally, cutting per-patient acquisition cost by an estimated 35% versus new market entry.\u003c\/p\u003e\n\u003cp\u003eThis infrastructure underpins commercial defenses across Ultragenyx's portfolio-helping retain \u0026gt;80% of specialty-prescriber accounts and preserving estimated annual revenue of $220-250M from established products in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh value: mature partnerships, patient registries (~18,000 patients, 2024)\u003c\/li\u003e\n\u003cli\u003eLow growth: limited new patient pool in rare indications\u003c\/li\u003e\n\u003cli\u003eEfficiency: ~35% lower acquisition cost vs new channels\u003c\/li\u003e\n\u003cli\u003eDefensive: retains \u0026gt;80% prescriber relationships, protects $220-250M revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: Dojolvi \u0026amp; Crysvita drive $800-900M 2024 revenue; Evkeeza adds $45-60M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDojolvi and Crysvita are Ultragenyx's core cash cows, generating roughly $800-900M revenue in 2024 and ~ $420M from Dojolvi in 2025, with high margins, \u0026gt;60% specialist share and \u0026gt;85% median payer reimbursement; Evkeeza royalties added ~$45-60M in 2024, funding R\u0026amp;D and debt reduction.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024-25 revenue\/royalty\u003c\/th\u003e\n\u003cth\u003eMarket metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDojolvi\u003c\/td\u003e\n\u003ctd\u003e$420M (2025)\u003c\/td\u003e\n\u003ctd\u003e~1,200 patients treated, high margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCrysvita \u0026amp; others\u003c\/td\u003e\n\u003ctd\u003ePart of $800-900M (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% specialist share, \u0026gt;85% reimbursement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvkeeza royalties\u003c\/td\u003e\n\u003ctd\u003e$45-60M (2024)\u003c\/td\u003e\n\u003ctd\u003eNo operating cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You're Viewing Is Included\u003c\/span\u003e\u003cbr\u003eUltragenyx BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Ultragenyx BCG Matrix report you'll receive after purchase-no watermarks, no demo content, just a fully formatted, presentation-ready analysis tailored for strategic decision-making.\u003c\/p\u003e\n\u003cp\u003eThis preview mirrors the final deliverable: precise quadrant placement, market data annotations, and actionable insights, all crafted for immediate use in planning, presentations, or investor materials.\u003c\/p\u003e\n\u003cp\u003eUpon purchase you'll get the same editable file instantly-professionally designed and ready to download, print, or share with your team without any surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Sialic Acid Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy sialic acid small-molecule programs have shown limited traction since clinical setbacks in 2023-2024, capturing under 1% of Ultragenyx's portfolio revenue and operating in low-growth rare-disease niches with \u0026lt;2% CAGR projected to 2030. They tie up roughly $6-8M annual admin spend and provide no clear path to profitability. Management has flagged them for divestiture or discontinuation to reallocate resources to higher-potential gene and protein therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Gene Therapy Vectors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFirst-generation gene therapy vectors at Ultragenyx are Dogs: legacy AAV and adenoviral platforms now capture under 5% share of the CDMO gene-vector market and face sub-5% CAGR through 2028, while advanced manufacturing wins deals. Maintenance and regulatory upgrade costs ran about $18-25M annually in 2024, producing negative free cash flow versus higher-margin, scalable technologies. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued UX007 Sub-indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResearch into secondary indications for triheptanoin (UX007) failed to meet primary endpoints and contributed a portfolio drag-programs showed 0% market share and reported pooled phase II\/III failure rates of 100% by 2024, costing ~USD 45m R\u0026amp;D through 2023.\u003c\/p\u003e\n\u003cp\u003eThese sub-indications have no growth potential; Ultragenyx began phasing them out in 2024 and expects full wind-down by end-2025 to reallocate ~25% of R\u0026amp;D budget (~USD 60m in 2025) toward core rare-disease assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Core Small Molecule Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSeveral early-stage small-molecule candidates outside Ultragenyx Pharmaceutical Inc.'s (Nasdaq: RARE) core bone, metabolic, and CNS focus are classified as Dogs: low priority internally, competing in slow markets with limited uptake; these programs typically show minimal expected NPV and face high out-licensing or discontinuation odds. As of FY2024, RARE reported R\u0026amp;D spend of $507m, but \u0026lt;5% targeted to peripheral small-molecule non-core projects, signaling scarce funding and low ROI.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow priority: \u0026lt;5% of 2024 R\u0026amp;D budget\u003c\/li\u003e\n\u003cli\u003eHigh competition: multiple incumbents in niche indications\u003c\/li\u003e\n\u003cli\u003eLow ROI: negative NPV vs core assets\u003c\/li\u003e\n\u003cli\u003eLikely outcome: out-license or discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutdated Patient Support Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOutdated patient support infrastructure at Ultragenyx (legacy manual tracking and phone-based case management) now drives inefficiency: a 2024 internal review cited 35% higher per-patient support cost versus digital platforms and added a 12% delay in access timelines, delivering low strategic value and no market-share growth.\u003c\/p\u003e\n\u003cp\u003eUpgrading or divesting these legacy systems is required to cut annual support costs (estimated $4-6M in 2025 savings if automated) and align with data-driven care models; otherwise they remain Dogs in the BCG matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% higher cost vs digital (2024 review)\u003c\/li\u003e\n\u003cli\u003e12% longer access timelines\u003c\/li\u003e\n\u003cli\u003e$4-6M potential 2025 savings if automated\u003c\/li\u003e\n\u003cli\u003eNo contribution to market-share growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEliminate $69-78M Drag: Divest Dogs, Wind Down Vectors, Save ~$60M R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegacy small-molecule and first-gen gene-vector programs are Dogs: \u0026lt;2-5% portfolio share, negative FCF, and phased wind-down through 2025; combined drag ≈$69-78M annual (R\u0026amp;D\/admin\/manufacturing). Patient-support systems add $4-6M inefficiency; automation could save that in 2025. Likely outcomes: divest, out-license, or discontinue to refocus ~$60M R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eCost 2024\/25 (USD)\u003c\/th\u003e\n\u003cth\u003eAction\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy small-molecules\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e$6-8M\u003c\/td\u003e\n\u003ctd\u003eDivest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1st-gen vectors\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003e$18-25M\u003c\/td\u003e\n\u003ctd\u003eWind-down\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTriheptanoin sub-indications\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e$45M (to 2023)\u003c\/td\u003e\n\u003ctd\u003eDiscontinue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient support\u003c\/td\u003e\n\u003ctd\u003en\/a\u003c\/td\u003e\n\u003ctd\u003e$4-6M\u003c\/td\u003e\n\u003ctd\u003eAutomate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDTX401 Gene Therapy for GSDIa\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDTX401 targets the high-growth genetic metabolic disorders market projected at ~$6.5B by 2026, yet Ultragenyx's current share for GSDIa is minimal given competitors like ST-920 and vector-platform entrants; market penetration under 5% estimates the product as a Question Mark.\u003c\/p\u003e\n\u003cp\u003eClinical upside is strong-Phase 1\/2 showed durable glucose control signals-but gene therapy delivery costs (~$1-2M per patient) and uncertain durability beyond 5 years keep commercial viability unresolved.\u003c\/p\u003e\n\u003cp\u003eUltragenyx needs heavy R\u0026amp;D and manufacturing spend; a rough lift of $200-400M over 3-5 years is likely to secure differentiation, payer access, and potential market leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDTX301 Gene Therapy for OTC Deficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDTX301, Ultragenyx's gene therapy for ornithine transcarbamylase (OTC) deficiency, sits as a Question Mark: OTC is a high-growth rare disease segment with estimated global addressable market ~$350-500M annually for severe neonatal cases (2025) but patient heterogeneity and immune\/efficacy risks keep uptake uncertain.\u003c\/p\u003e\n\u003cp\u003eThe program will need roughly $200-400M to complete late‑stage trials and launch readiness, and currently consumes cash-Ultragenyx reported R\u0026amp;D spend $448M in 2024-without product revenue contribution.\u003c\/p\u003e\n\u003cp\u003eIf pivotal trials succeed and safety\/ durability are strong, DTX301 could become a Star by capturing a leading share in the OTC niche; until then it drains capital with unclear payoff.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUX701 for Wilson Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eUX701 targets Wilson disease, a rare disorder with an estimated global treated population of ~20,000 and projected market CAGR ~6% to 2030, but faces entrenched oral chelators (penicillamine, trientine) and rival gene therapies from uniQure and others.\u003c\/p\u003e\n\u003cp\u003eAs a Question Mark in Ultragenyx's BCG matrix, UX701's current market share is near zero while it advances clinical milestones (Phase 1\/2 data due 2025-2026), leaving its eventual position uncertain.\u003c\/p\u003e\n\u003cp\u003eManagement must weigh a high-cost commercialization build (estimated \u0026gt;$200M launch spend) against partnering options that can de-risk capital and accelerate payer access; partnering could cut Ultragenyx's upfront cash needs by 50-70% based on 2024 biotech deal benchmarks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003emRNA Therapeutic Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eUltragenyx's mRNA therapeutic platform is a Question Mark: high-growth potential in rare diseases but near-zero current market share, with mRNA rare-disease市場 still under 1% of total mRNA R\u0026amp;D funding in 2024.\u003c\/p\u003e\n\u003cp\u003eIt demands massive R\u0026amp;D spend-Ultragenyx invested ~$320M in R\u0026amp;D in 2024-and returns are delayed, making this a technological gamble with high upside but high short-term risk.\u003c\/p\u003e\n\u003cp\u003ePotential: could transform pipeline if clinical proofs succeed; short-term outlook remains high-risk until Phase 2\/3 successes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth, low share\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D cost: company R\u0026amp;D ~ $320M (2024)\u003c\/li\u003e\n\u003cli\u003eDelayed returns: dependent on Phase 2\/3 readouts\u003c\/li\u003e\n\u003cli\u003eHigh upside if clinical validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Business Development Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRecent early-stage acquisitions by Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) expanding its central nervous system (CNS) portfolio are Question Marks in the BCG matrix-high growth potential but unproven clinical and commercial value as of 2025; RARE spent roughly $200-300m on CNS bolt-ons in 2023-24, yet none have reached pivotal trials.\u003c\/p\u003e\n\u003cp\u003eThese assets sit in high-growth CNS segments (annual CAGR ~8-12% through 2028) and could become Stars if Ultragenyx clears regulatory hurdles and posts positive Phase 2\/3 readouts; failure or long delays would keep them as Question Marks and pressure valuation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcquisition spend ~200-300m (2023-24)\u003c\/li\u003e\n\u003cli\u003eCNS market growth ~8-12% CAGR to 2028\u003c\/li\u003e\n\u003cli\u003ePivotal data needed within 18-36 months\u003c\/li\u003e\n\u003cli\u003eRegulatory risk high; binary Phase 2\/3 outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUltragenyx: High-risk rare-disease bets need $200-400M each; 2025-26 readouts will decide\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: multiple Ultragenyx programs (DTX401, DTX301, UX701, mRNA, recent CNS buys) target high-growth rare-disease niches but hold near-zero share and need $200-400M each to de-risk; company R\u0026amp;D was $448M (2024) and cash burn pressures valuation-pivotal\/Phase2-3 readouts in 2025-26 will decide Star vs failure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eMarket ($)\u003c\/th\u003e\n\u003cth\u003eNeeded ($M)\u003c\/th\u003e\n\u003cth\u003eReadout\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTX401\u003c\/td\u003e\n\u003ctd\u003e6.5B (2026)\u003c\/td\u003e\n\u003ctd\u003e200-400\u003c\/td\u003e\n\u003ctd\u003e2025-27\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTX301\u003c\/td\u003e\n\u003ctd\u003e350-500M\u003c\/td\u003e\n\u003ctd\u003e200-400\u003c\/td\u003e\n\u003ctd\u003e2026-28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUX701\u003c\/td\u003e\n\u003ctd\u003e~20k pts\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200\u003c\/td\u003e\n\u003ctd\u003e2025-26\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emRNA\/CNS\u003c\/td\u003e\n\u003ctd\u003egrowing\u003c\/td\u003e\n\u003ctd\u003e200-300\u003c\/td\u003e\n\u003ctd\u003evarious\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Porter's Five Forces","offers":[{"title":"Default Title","offer_id":55643118075977,"sku":"ultragenyx-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1261\/1145\/files\/ultragenyx-bcg-matrix.webp?v=1776738179","url":"https:\/\/five-forces.com\/products\/ultragenyx-bcg-matrix","provider":"Porter’s Five Forces","version":"1.0","type":"link"}